A new analysis of recent research casts doubt on the continued efficacy of fluoxetine, commonly known as Prozac, as a treatment for adolescent depression. Published November 21, 2025, the study suggests the widely prescribed antidepressant may now perform no better than a placebo for young people, raising urgent questions about current clinical guidelines and a treatment landscape already challenged by rising rates of youth mental health concerns [[3]]. While fluoxetine remains the sole approved antidepressant for this age group in France, and is a common first-line treatment in the US, emerging data points to a potential decline in its effectiveness, potentially linked to factors beyond the drug itself.
The widely prescribed antidepressant fluoxetine, known as Prozac, may no longer be clinically effective in treating depression in adolescents, according to a new analysis of available research. The findings, published November 21, 2025, in the Journal of Clinical Epidemiology, suggest a need to re-evaluate current treatment guidelines for young people struggling with depression, a growing concern for public health officials.
While fluoxetine remains the only medication authorized in France for treating pediatric depression, researchers found that recent studies indicate the drug no longer meets established thresholds for clinical relevance. The analysis highlights a concerning trend: despite its continued recommendation as a first-line treatment, the evidence supporting fluoxetine’s efficacy in this population is weakening.
Evolution of Available Studies
Initial meta-analyses, including research from Cipriani in 2016 and Zhou in 2020, suggested a statistical advantage of Prozac over a placebo. However, these conclusions were based on data considered “very weak” in terms of confidence levels. A 2021 Cochrane review further reinforced these doubts, concluding that the difference between the medication and the placebo was “small and of questionable importance.” The authors of that review questioned whether antidepressants should be used at all in this age group.
The recent study builds on this body of evidence, suggesting the perceived effectiveness of fluoxetine may be influenced by a “novelty bias” and diminishing “expectancy effects” in more recent trials. Early trials, where fluoxetine was a newer medication, showed more significant effects than those where it was used as a comparison drug. Since 2022, confidence intervals have consistently fallen below the threshold for clinical significance, indicating an equivalence to a placebo.
Possible Explanations for Reduced Efficacy
Researchers propose that the decline in perceived effectiveness could be linked to the way trials are conducted. The “novelty bias” suggests that patients may respond more positively to a new treatment simply because it is new. Diminished “expectancy effects” mean that patients in more recent trials may have lower expectations of improvement, potentially influencing outcomes.
Despite these findings, the study authors noted a lack of recognition of these results in current recommendations. Several organizations continue to list fluoxetine as a first-line treatment for adolescent depression. In France, the Haute Autorité de santé, in its November 2014 recommendations regarding depressive symptoms in adolescents, specifies that fluoxetine is the recommended antidepressant for initial treatment in primary care settings.
The study’s findings underscore the importance of ongoing evaluation of treatment efficacy and the need for updated clinical guidelines to reflect the latest research. Further investigation into the long-term effects of antidepressant use in adolescents is also crucial, as current trials are often short in duration and lack comprehensive data on long-term outcomes.
